Literature DB >> 1601757

Cerebrospinal fluid penetration of cefpirome in patients with non-inflamed meninges.

D E Nix1, J H Wilton, N Velasquez, J L Budny, H B Lassman, P Mitchell, K Divan, J J Schentag.   

Abstract

Twenty patients (mean age 52 +/- 12 years, mean weight 75 +/- 15 kg) scheduled for elective myelogram or spinal anaesthesia were enrolled to determine the cerebrospinal fluid (CSF) penetration of a new expanded spectrum cephalosporin antibiotic, cefpirome (HR-810). A single 2 g intravenous dose of cefpirome was administered as a bolus between 1 and 8 h before lumbar puncture. Blood samples were collected at 15 pre-determined times and a single CSF sample was obtained at the time of lumbar puncture. Serum and CSF cefpirome concentrations were determined by high performance liquid chromatography. The mean maximal serum concentration of cefpirome was 264 +/- 76 mg/L. A mean steady-state volume of distribution of 20 +/- 4 L, clearance of 7.4 +/- 1.3 L/h, and half-life of 2.5 +/- 0.5 h were determined. Mean CSF concentrations were 0.50 +/- 0.11 mg/L at 1-2 h post dose (n = 4), 0.57 +/- 0.13 mg/L at 2-4 h post dose (n = 4), 0.76 +/- 0.34 mg/L at 4-6 h post dose (n = 7), and 0.83 +/- 0.29 mg/L at 6-8.3 h post dose (n = 5). Blood:brain barrier permeability to cefpirome may not be a limiting factor as CSF concentrations were rapidly attained. Further studies are required to determine the mechanism of cefpirome transport between plasma and CSF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1601757     DOI: 10.1093/jac/29.suppl_a.51

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.

Authors:  L R Wiseman; H M Lamb
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

2.  Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man.

Authors:  R Nau; G Zysk; A Thiel; H W Prange
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 3.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 4.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 5.  Cefpirome clinical pharmacokinetics.

Authors:  L C Strenkoski; D E Nix
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

6.  Pharmacokinetics of cefpirome in pediatric patients.

Authors:  M C Nahata; W J Barson; S K Puri
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.